摘要
目的评估茚达特罗/格隆溴铵与沙美特罗/氟替卡松治疗中度至极重度慢性阻塞性肺疾病(COPD)的成本-效果,为临床用药决策提供依据。方法利用Markov模型队列模拟分析法预估两种药物治疗COPD的远期效果和费用。结果茚达特罗/格隆溴铵和沙美特罗/氟替卡松治疗每例COPD患者的平均费用分别为86393.01元和81537.16元,分别获得5.47和5.32个质量调整生命年(QALYs)。茚达特罗/格隆溴铵相较于沙美特罗/氟替卡松的增量成本效果比(ICER)为32372.33元/QALY。结论在意愿支付水平内,与沙美特罗/氟替卡松相比,茚达特罗/格隆溴铵治疗COPD的成本略高,效果略好。
Objective To assess the cost-effectiveness indacaterol/glycopyrrolate FDC in patients with moderate to very severe chronic obstructive pulmonary diseases(COPD)in China,and to provide a basis for clinical medication decisions.Methods Markov model cohort simulation was used to estimate the long-term efficacy and cost of two drugs for COPD.Results The average cost of indacaterol/glycopyrrolate FDC and salmeterol/fluticasone for the treatment of COPD were 86393.01 yuan,81537.16 yuan,respectively,and obtained 5.47 and 5.32 QALYs.The ICER of indacaterol/glycopyrrolate FDC compared with salmeterol/fluticasone was 32372.33 yuan/QALY.Conclusion Indacaterol/glycopyrrolate FDC is slightly more costly and effective in treating COPD than salmeterol/fluticasone at the level of willingness to pay.
作者
周媛
阎爱荣
ZHOU Yuan;YAN Airong(School of Pharmacy,Shanxi Medical University,Taiyuan 030001,China;Drug Clinical Trial Institution,Shanxi Provincial People's Hospital,Taiyuan 030012,China)
出处
《医药导报》
CAS
北大核心
2021年第1期115-120,共6页
Herald of Medicine
